株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

BRAFキナーゼ阻害剤の世界市場:2019年~2023年

Global BRAF Kinase Inhibitors Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 865018
出版日 ページ情報 英文 125 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.43円で換算しております。
Back to Top
BRAFキナーゼ阻害剤の世界市場:2019年~2023年 Global BRAF Kinase Inhibitors Market 2019-2023
出版日: 2019年05月17日 ページ情報: 英文 125 Pages
概要

ダブラフェニブおよびソラフェニブなどのBRAFキナーゼ阻害剤に基づく優れた薬物は、HCC、RCC、NSCLC、および黒色腫の治療戦略に革命をもたらしています。しかしながら、これらの薬物の高コストは、患者にとっても医療システムにとっても課題です。この課題を克服するために、製薬会社を含む多くの政府機関および非政府機関は、様々な癌適応症の治療のための財政的支援および臨床的支援の提供に力を入れています。効果的な患者支援プログラムと償還プログラムは、BRAFキナーゼ阻害剤の高コスト治療法の大きな助けになることが期待されており、治療法を利用する患者が増えるように促し、それによって市場の成長が促進されます。 Technavioのアナリストは、世界のBRAFキナーゼ阻害剤市場が2023年までに8%以上のCAGRで成長すると予測しています。

当レポートでは、世界のBRAFキナーゼ阻害剤市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • ダブラフェニブ
  • ソラフェニブ
  • ベムラフェニブ
  • エンコラフェニブ
  • 市場機会:製品別

第7章 顧客情勢

第8章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第10章 市場動向

第11章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Array BioPharma Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG

第13章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第14章 TECHNAVIOについて

図表
  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Dabrafenib - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Dabrafenib - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Sorafenib - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Sales data of sorafenib
  • Exhibit 23: Sorafenib - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Vemurafenib - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Vemurafenib - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Encorafenib - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Encorafenib - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Market opportunity by product
  • Exhibit 29: Customer landscape
  • Exhibit 30: Market share by geography 2018-2023 (%)
  • Exhibit 31: Geographic comparison
  • Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in North America
  • Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Europe
  • Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in Asia
  • Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 43: Top 3 countries in ROW
  • Exhibit 44: Key leading countries
  • Exhibit 45: Market opportunity
  • Exhibit 46: Patient assistance programs
  • Exhibit 47: New cases of cancer in the US 2015
  • Exhibit 48: Alternative therapies based on BRAF kinase inhibitors for various oncology indications
  • Exhibit 49: Side effects of BRAF kinase inhibitors
  • Exhibit 50: Impact of drivers and challenges
  • Exhibit 51: Approved drugs with respect to their cancer indications
  • Exhibit 52: Expansion of research areas of BRAF kinase inhibitors
  • Exhibit 53: Strategic alliances in global BRAF kinase inhibitors market
  • Exhibit 54: Vendor landscape
  • Exhibit 55: Landscape disruption
  • Exhibit 56: Vendors covered
  • Exhibit 57: Vendor classification
  • Exhibit 58: Market positioning of vendors
  • Exhibit 59: Array BioPharma Inc. - Vendor overview
  • Exhibit 60: Array BioPharma Inc. - Business segments
  • Exhibit 61: Array BioPharma Inc. - Organizational developments
  • Exhibit 62: Array BioPharma Inc. - Geographic focus
  • Exhibit 63: Array BioPharma Inc. - Key offerings
  • Exhibit 64: Array BioPharma Inc. - Key customers
  • Exhibit 65: Bayer AG - Vendor overview
  • Exhibit 66: Bayer AG - Business segments
  • Exhibit 67: Bayer AG - Organizational developments
  • Exhibit 68: Bayer AG - Geographic focus
  • Exhibit 69: Bayer AG - Segment focus
  • Exhibit 70: Bayer AG - Key offerings
  • Exhibit 71: Bayer AG - Key customers
  • Exhibit 72: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 73: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 74: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 75: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 76: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 77: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 78: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 79: Novartis AG - Vendor overview
  • Exhibit 80: Novartis AG - Business segments
  • Exhibit 81: Novartis AG - Organizational developments
  • Exhibit 82: Novartis AG - Geographic focus
  • Exhibit 83: Novartis AG - Segment focus
  • Exhibit 84: Novartis AG - Key offerings
  • Exhibit 85: Novartis AG - Key customers
  • Exhibit 86: Validation techniques employed for market sizing
  • Exhibit 87: Definition of market positioning of vendors
目次
Product Code: IRTNTR31351

About this market

Prominent drugs based on BRAF kinase inhibitors, such as dabrafenib and sorafenib, are revolutionizing the therapeutic strategies of HCC, RCC, NSCLC, and melanomas. However, the high costs of these drugs remain a challenge to patients as well as the healthcare system. To overcome this challenge, many government and non-government organizations, including pharmaceutical companies, are focusing on providing financial assistance and clinical assistance for the treatment of various cancer indications. Effective patient assistance programs and reimbursement programs are expected to help with the high-cost regimen of BRAF kinase inhibitors to a large extent, which would encourage more patients to avail the treatment, thereby driving the market growth. Technavio's analysts have predicted that the BRAF kinase inhibitors market will register a CAGR of over 8% by 2023.

Market Overview

Increasing prevalence of cancer

The prevalence of cancer has seen a significant rise in recent years globally, and the global pharmaceuticals market has witnessed the approval of various novel therapies, especially in the field of oncology. Hence, various companies are conducting heavy research on developing novel therapeutics, such as BRAF kinase inhibitors, to capture the huge unmet need, and the market has witnessed the approval of these drugs in the last two decades. Currently, BRAF kinase inhibitors are approved for some of the major cancers such as NSCLC, metastatic melanomas, and RCC. Therefore, the strong prevalence of various cancer indications is driving the growth of the global BRAF kinase inhibitors market.

Adverse effects of available drugs

BRAF kinase inhibitor therapeutics demonstrate a range of adverse effects such as fatigue, muscle cramps, nausea, vomiting, and diarrhea. The combination of BRAF kinase inhibitors and radiation therapy often leads to cytotoxic effects and myelosuppression. Despite being highly efficacious, the BRAF kinase inhibitors used for treating some of the oncology indications are associated with a spectrum of side effects. These side effects limit patient adherence to treatments, which poses a challenge to the market.

For the detailed list of factors that will drive and challenge the growth of the BRAF kinase inhibitors market during 2019-2023.

Competitive Landscape

The market appears to be moderately concentrated. The presence of few companies, including Array BioPharma Inc. and Bayer AG makes the competitive environment quite intense. Factors such as the improvements in production technology of BRAF kinase inhibitors and the growing demand for renewable energy and sustainable products will provide significant growth opportunities to the BRAF kinase inhibitor drug manufacturers. F. Hoffmann-La Roche Ltd., and Novartis AG. are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Dabrafenib - Market size and forecast 2018-2023
  • Sorafenib - Market size and forecast 2018-2023
  • Vemurafenib - Market size and forecast 2018-2023
  • Encorafenib - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Array BioPharma Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 14: EXPLORE TECHNAVIO

Back to Top